PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir
Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit Royalties DURHAM, N.C. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a
View HTML
Toggle Summary Chimerix to Present at 2019 Cantor Global Healthcare Conference
DURHAM, N.C. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. ET in New York City.
View HTML
Toggle Summary Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line Acute Myeloid Leukemia Planned to Initiate in Mid 2020 Finalizing Animal Studies of Brincidofovir as Smallpox Medical
View HTML
Toggle Summary Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia
        Transformational Transaction Provides Key Program in First-Line Acute Myeloid Leukemia with Fast Track and Orphan Drug Designations and Potential Utility as a Platform Technology                 Phase II Randomized Data Presented at ASCO 2019 Demonstrated Compelling Complete Response Rates,
View HTML
Toggle Summary Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities – – Restructuring to Reduce Workforce by More Than 50%,
View HTML
Toggle Summary Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019
DURHAM, N.C. , May 02, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, May 9, 2019 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Management Updates
Mike Sherman Appointed Chief Executive Officer and Mike Andriole Appointed Chief Business Officer DURHAM, N.C. , April 08, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of
View HTML
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 39th Annual Health Care Conference
DURHAM, N.C. , March 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that Timothy Trost , Chief Financial Officer of Chimerix, will present at the Cowen and Company 39th Annual
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
DURHAM, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Tuesday, March 5, 2019 at 8:30 a.m.
View HTML